ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board
ResMed (NYSE: RMD, ASX: RMD) has expanded its board of directors to 11 members by appointing Christopher DelOrefice, the current CFO of Becton, Dickinson and Company (BD). DelOrefice brings over 30 years of strategic and operational finance expertise to ResMed's board. He will also serve on the board's audit committee. DelOrefice's appointment is effective immediately, and he will stand for re-election at ResMed's annual meeting on November 21, 2024.
Prior to joining BD, DelOrefice held various leadership roles at Johnson & Johnson, including vice president of investor relations and CFO of J&J's consumer and medical device business segments for North America. His experience also includes positions at AstraZeneca, AET Films, and Ametek. ResMed's CEO, Mick Farrell, praised DelOrefice's achievements and leadership capabilities, noting that his financial experience in healthcare and medical technology will complement the existing board members.
ResMed (NYSE: RMD, ASX: RMD) ha ampliato il suo consiglio di amministrazione a 11 membri nominando Christopher DelOrefice, l'attuale CFO di Becton, Dickinson and Company (BD). DelOrefice porta oltre 30 anni di esperienza in finanza strategica e operativa al consiglio di ResMed. Inoltre, farà parte del comitato di revisione del consiglio. La nomina di DelOrefice è immediatamente efficace e si presenterà per la rielezione all'assemblea annuale di ResMed, prevista per il 21 novembre 2024.
Prima di entrare in BD, DelOrefice ha ricoperto vari ruoli di leadership presso Johnson & Johnson, inclusi vice presidente delle relazioni con gli investitori e CFO dei segmenti consumer e medical devices per il Nord America. La sua esperienza comprende anche posizioni in AstraZeneca, AET Films e Ametek. Il CEO di ResMed, Mick Farrell, ha elogiato i successi e le capacità di leadership di DelOrefice, evidenziando che la sua esperienza finanziaria nel settore della salute e della tecnologia medica completerà i membri attuali del consiglio.
ResMed (NYSE: RMD, ASX: RMD) ha ampliado su junta directiva a 11 miembros nombrando a Christopher DelOrefice, el actual CFO de Becton, Dickinson and Company (BD). DelOrefice aporta más de 30 años de experiencia en finanzas estratégicas y operativas a la junta de ResMed. También formará parte del comité de auditoría de la junta. La nombramiento de DelOrefice es efectiva de inmediato y se presentará a la reelección en la reunión anual de ResMed programada para el 21 de noviembre de 2024.
Antes de unirse a BD, DelOrefice ocupó varios roles de liderazgo en Johnson & Johnson, incluyendo vicepresidente de relaciones con inversores y CFO de los segmentos de consumo y dispositivos médicos de J&J para América del Norte. Su experiencia también incluye posiciones en AstraZeneca, AET Films y Ametek. El CEO de ResMed, Mick Farrell, elogió los logros y las capacidades de liderazgo de DelOrefice, señalando que su experiencia financiera en el sector de la salud y la tecnología médica complementará a los miembros actuales de la junta.
ResMed (NYSE: RMD, ASX: RMD)는 이사회를 11명으로 확장했습니다, 현재 Becton, Dickinson and Company (BD)의 CFO인 Christopher DelOrefice를 임명했습니다. DelOrefice는 ResMed 이사회에 30년 이상의 전략 및 운영 재무 전문성을 제공합니다. 그는 또한 이사회의 감사 위원회에서 활동하게 됩니다. DelOrefice의 임명은 즉시 발효되며, 그는 2024년 11월 21일에 예정된 ResMed의 연례 회의에서 재선에 나설 것입니다.
BD에 합류하기 전, DelOrefice는 Johnson & Johnson에서 투자자 관계 부사장 및 J&J의 소비자 및 의료 기기 부문의 CFO를 포함한 다양한 리더십 역할을 담당했습니다. 그의 경험은 AstraZeneca, AET Films 및 Ametek에서의 직책도 포함됩니다. ResMed의 CEO인 Mick Farrell은 DelOrefice의 성과와 리더십 역량을 높이 평가하며, 그가 보건 및 의료 기술 분야에서의 재무 경험이 기존 이사들과 잘 조화를 이룰 것이라고 언급했습니다.
ResMed (NYSE: RMD, ASX: RMD) a élargi son conseil d'administration à 11 membres en nommant Christopher DelOrefice, l'actuel CFO de Becton, Dickinson and Company (BD). DelOrefice apporte plus de 30 ans d'expertise dans les domaines de la finance stratégique et opérationnelle au conseil de ResMed. Il siègera également au comité d'audit du conseil. La nomination de DelOrefice prend effet immédiatement et il se présentera à la réélection lors de l'assemblée annuelle de ResMed prévue le 21 novembre 2024.
Avant de rejoindre BD, DelOrefice a occupé divers postes de direction chez Johnson & Johnson, notamment vice-président des relations avec les investisseurs et CFO des segments d'activité consommables et dispositifs médicaux de J&J pour l'Amérique du Nord. Son expérience comprend également des postes chez AstraZeneca, AET Films et Ametek. Le PDG de ResMed, Mick Farrell, a salué les réalisations et les capacités de leadership de DelOrefice, notant que son expérience financière dans le secteur de la santé et de la technologie médicale complétera les membres actuels du conseil.
ResMed (NYSE: RMD, ASX: RMD) hat seinen Vorstand auf 11 Mitglieder erweitert, indem Christopher DelOrefice, der derzeitige CFO von Becton, Dickinson and Company (BD), ernannt wurde. DelOrefice bringt über 30 Jahre strategische und operative Finanzerfahrung in den Vorstand von ResMed ein. Er wird außerdem im Prüfungsausschuss des Vorstands tätig sein. DelOrefices Ernennung ist sofort wirksam und er wird sich bei der Jahresversammlung von ResMed am 21. November 2024 zur Wiederwahl stellen.
Vor seinem Eintritt bei BD hatte DelOrefice verschiedene Führungspositionen bei Johnson & Johnson inne, darunter Vizepräsident für Investor Relations und CFO der Geschäftssegmente Konsumgüter und Medizintechnik für Nordamerika. Zu seinen Erfahrungen zählen auch Positionen bei AstraZeneca, AET Films und Ametek. Mick Farrell, der CEO von ResMed, lobte DelOrefices Erfolge und Führungsfähigkeiten und stellte fest, dass seine Finanzerfahrung im Gesundheitswesen und der Medizintechnologie die bestehenden Vorstandsmitglieder ergänzen wird.
- Expansion of board to 11 members, potentially bringing more diverse expertise
- Appointment of Christopher DelOrefice, a seasoned finance leader with over 30 years of experience
- DelOrefice's current role as CFO of BD, a large global MedTech company, bringing relevant industry insight
- Addition of DelOrefice to the board's audit committee, potentially strengthening financial oversight
- None.
- DelOrefice is the Chief Financial Officer at BD, one of the largest global MedTech companies in the world
- Board appointment brings over 30 years of strategic and operational finance expertise
SAN DIEGO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it has expanded the size of its board of directors to 11 and has elected Christopher DelOrefice to the board, effective immediately. Mr. DelOrefice was appointed during ResMed’s regularly scheduled board meeting on August 15, 2024, and will stand for re-election with the rest of ResMed’s directors at its annual meeting on November 21, 2024. Mr. DelOrefice has also been appointed as a member of ResMed’s board audit committee.
DelOrefice currently serves as executive vice president and chief financial officer (CFO) of Becton, Dickinson and Company (BD) and brings over 30 years of audit, finance, and strategic expertise to augment and strengthen ResMed’s diverse board. Before joining BD in September 2021, DelOrefice served in many roles at Johnson & Johnson (J&J), including most recently as vice president of investor relations and previously as CFO of J&J’s consumer and medical device business segments for North America, along with roles in finance leadership for supply chain, corporate mergers and acquisitions, consumer research and development, and business development for J&J’s North America pharmaceutical business. Before J&J, DelOrefice held positions of increasing responsibility in accounting, global audit, and financial reporting at AstraZeneca, AET Films, and Ametek.
“I’m pleased to welcome Christopher DelOrefice to ResMed’s Board,” said Mick Farrell, Chairman and CEO of ResMed. “Chris has proven himself an experienced global leader in corporate finance and business strategy, as well as in global operations management across multiple business sectors, including in his current role as CFO of a multi-billion dollar, global MedTech company. My fellow board members and I were impressed with Chris’ achievements, as well as his humility, hard-working nature, and leadership capabilities, all of which are highly relevant to his service as a ResMed director. Chris’ financial experience in healthcare and medical technology at BD, J&J, and AstraZeneca will complement the leaders already serving as ResMed directors.”
DelOrefice holds a Master of Business Administration and a Bachelor of Science in Accounting from Villanova University. He remains actively engaged in student career mentoring and development initiatives at his alma mater. DelOrefice received his certified public accountant (CPA) license (inactive) from the Commonwealth of Pennsylvania.
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
| For investors | For media |
| +1 858.836.5971 | +1 619.510.1281 |
| investorrelations@resmed.com | news@resmed.com |
FAQ
Who is the new board member appointed to ResMed's (RMD) board of directors?
When will Christopher DelOrefice stand for re-election to ResMed's (RMD) board?
What is Christopher DelOrefice's background before joining ResMed's (RMD) board?
How many members are now on ResMed's (RMD) board of directors?
